The award-winning BioCopy team covers both, business know-how and scientific expertise in various fields, such as biology, physics, manufacturing systems technology, assay development and microsystems technology. The expertise of the team, headed by Dr. Günter Roth, is complemented by renowned board members like Dr. Alexander van Gabain, Dr. Thomas Langer and Dr. Pascal Brenneisen.
Dr. Alexander van Gabain
Alexander von Gabain is a microbiologist, scientist, founder of several biotech companies and board member of venture capital companies. Throughout his career, he has worked at the interface of healthcare, science and research. As co-founder of Intercell AG, he was able to register and market a novel vaccine against Japanese Encephalitis worldwide. Alexander von Gabain is CEO of INiTS, the Technology Seed Fund and Incubator of the University of Vienna and he is Chairman of the Board of the European Institute of Innovation and Technology (EIT). His commitment underlines the importance of BioCopy technology for the vaccine market.
Dr. Pascal Brenneisen
Pascal Brenneisen is a senior executive with work experience in over 25 countries. He possesses a rich mix of expertise in general management of countries and regions, strategic business development, sales and marketing, operations, finance and operational auditing in the industries of pharmaceuticals, health care and fast-moving consumer goods. In addition to his extensive contributions to healthcare and pharmaceutical giants including Novartis (as President of Novartis Switzerland) and Sandoz (CEO UK & Ireland), he has served on various boards including Konapharma Ltd., Entourage Pharma Consulting Ltd., Topadur Pharma Ltd., and Brenneisen LifeScience GmbH. Pascal will be managing the contact and engagement with key partners for development and future commercialization of BioCopy’s products/services.
Dr. Thomas Langer
Thomas has experience in investing biotechnological start-ups and in supporting them with strategies about financing and sales, and he also carries out these functions in BioCopy. Thanks to his professional background, has helped in the definition of the most accurate ways to sell the BioCopy. In the project, he will secure the post-project financing from banks or venture capital companies and will negotiate with them the conditions of payments or the distribution of shares.
Dr. Günter Roth
Dr. Günter Roth is the main inventor of the patents of copying technology. Dr. Roth is a graduate physicist and graduate biochemist and has a comprehensive, interdisciplinary education. From 2008-2013 he was at the chair of Prof. Dr. Zengerle head of the group „Assay development “ and led the development of microfluidic systems and assays. He was involved in about 30 publications. During this time he developed the copying of biomolecules. From June 2013 to August 2018, he was head of a research group at the ZBSA (University of Freiburg) for the development of various applications of the biomolecule copy.
He holds a BSc in Biochemistry, Genetics, Limnology and a MSc in Biology from the University of Freiburg (Germany), and an MBA from Edinburgh Business School. Thanks to his interdisciplinary knowledge in business & science, Niko has accumulated more than 10 years of experience in business development. He has worked in different biotech companies, thanks to which he has an in-depth know-how in various life science technologies and markets. His work experience includes: Marketing and sales at Genolife SA, Project Manager at Metabolic Explorer, Business Developer at Charles River Discovery Research Services Germany GmbH or Marketing Manager at Genedata. Niko has also worked as Business Developer and Innovation Manager at the Office for Technology Transfer from the University of Freiburg. There, he was initiator and Project Manager of the business plan competition „Startinsland“ and co-founder of the start-up BioCopy GmbH. At present, Niko works as Business Development at Thermo Fisher Scientific/Phadia Freiburg.